<?xml version="1.0" encoding="UTF-8"?>
<p>In addition to its immune-boosting effect, thymosin Î±1 was recently suggested to facilitate the infiltration of immune cells to improve the effectiveness of checkpoint inhibitors [
 <xref rid="B63-pharmaceuticals-13-00096" ref-type="bibr">63</xref>]. As an immune-boosting agent, the drug is registered for several clinical trials in combination with antiviral agents for the treatment of COVID-19 (NCT04252274 and ChiCTR2000029541).
</p>
